Finance

Lists
RGEN:NASDAQ
Repligen Corp
$176.89
-0.73%
(-1.30) 1D
$176.89
-0.00% (-0.0025)
After hours
Closed: Sep 18, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RGEN...
Open
$179.10
High
$179.10
Low
$176.29
Mkt. cap
9.98B
Avg. vol.
960.43K
Volume
1.36M
P/E ratio
241.12
52-wk high
$188.73
52-wk low
$100.99
EPS
$0.73
Beta
1.05
Shares outstanding
56.44M
No. of employees
2K
Open
$179.10
High
$179.10
Low
$176.29
Mkt. cap
9.98B
Avg. vol.
960.43K
Volume
1.36M
P/E ratio
241.12
52-wk high
$188.73
52-wk low
$100.99
EPS
$0.73
Beta
1.05
Shares outstanding
56.44M
No. of employees
2K
News stories
From web sources and news partners
Profile
Repligen Corporation is an American life sciences company that develops and manufactures products used in biological drug manufacturing. The company is headquartered in Waltham, Massachusetts, and is listed on the Nasdaq under the symbol RGEN. Wikipedia
About Repligen Corp
CEOTony J. Hunt
Employees2K
Founded1981
HeadquartersWaltham, Massachusetts, United States
SectorHealth care
Websiterepligen.com
Analyst ratings
Based on 12 analysts giving stock ratings to RGEN in the past 3 months
Strong buy
Buy
11
Hold
1
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for RGEN in the last 3 months.
Highest
Current $176.89
$225.00 (+27.20%)
Average
$181.67 (+2.70%)
Lowest
$145.00 (-18.03%)
Analyst
Recommendation
Action
Price target
Projected
Date
Daniel Arias
Stifel Nicolaus
Buy
Maintained
-
-
09/15/2026
Unknown Analyst
UBS
Buy
Maintained
$225.00
+27.2%
09/09/2026
Doug Schenkel
UBS
Buy
Maintained
$225.00
+27.2%
09/09/2026
Evan Stampler
Wells Fargo
Buy
Maintained
$185.00
+4.6%
08/16/2026
Brandon Couillard
Wells Fargo
Buy
Maintained
$185.00
+4.6%
07/30/2026
Kyle Mikson CFA
Canaccord Genuity
Hold
Maintained
$145.00
-18%
07/28/2026
Casey Woodring
J.P. Morgan
Buy
Reiterated
$175.00
-1.1%
07/29/2026
Dan Leonard
RBC Capital
Buy
Reiterated
$185.00
+4.6%
07/28/2026
Brendan Smith
TD Cowen
Buy
Maintained
$200.00
+13.1%
07/28/2026
Matt Larew
William Blair
Buy
Maintained
-
-
07/28/2026
Luke Sergott
Barclays
Buy
Maintained
$175.00
-1.1%
07/28/2026
Robert Wasserman
Benchmark Co.
Buy
Upgraded
$185.00
+4.6%
07/07/2026
Daniel Markowitz CFA
Evercore ISI
Buy
Maintained
$160.00
-9.5%
07/06/2026
Matt Hewitt
Craig-Hallum
Buy
Maintained
-
-
06/24/2026
Yessica Sanchez Gudino
HSBC
Buy
Maintained
$150.00
-15.2%
06/03/2026
Unknown Analyst
HSBC
Buy
Maintained
$150.00
-15.2%
06/03/2026
Michael Polark
Wolfe Research
Buy
Initiated
$145.00
-18%
06/01/2026
Unknown Analyst
RBC Capital
Buy
Initiated
$160.00
-9.5%
05/14/2026
Unknown Analyst
Guggenheim
Hold
Reiterated
-
-
05/07/2026
Matthew Stanton, CFA
Jefferies
Hold
Maintained
$142.00
-19.7%
05/05/2026
Natalya Davies
Rothschild & Co Redburn
Buy
Initiated
$160.00
-9.5%
04/17/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$208.00
+17.6%
03/23/2026
Subbu Nambi
Guggenheim
Hold
Maintained
-
-
02/24/2026
Paul Knight
KeyBanc
Buy
Maintained
$220.00
+24.4%
02/25/2026
Last report
Jul 28, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.54 / $0.51
+6.26%beat
Revenue / Est. (USD)
204.13M / 204.72M
-0.29%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
188.80M
197.91M
194.26M
204.13M
Cost of goods sold
88.29M
94.08M
85.97M
94.09M
Cost of revenue
88.29M
94.08M
85.97M
94.09M
Research and development expenses
14.18M
13.12M
14.46M
14.42M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
73.66M
74.36M
76.54M
76.62M
Operating expense
87.84M
87.48M
90.99M
91.04M
Total operating expenses
176.13M
181.56M
176.96M
185.13M
Operating income
12.68M
16.35M
17.29M
19.00M
Other non operating income
-446.00K
-11.48M
-750.00K
-273.00K
EBT including unusual items
17.11M
19.11M
1.77M
14.15M
EBT excluding unusual items
12.96M
17.59M
16.88M
19.08M
Income tax expense
2.20M
5.83M
-6.56M
9.14M
Effective tax rate
12.86%
30.48%
-370.26%
64.62%
Other operating expenses
-
-
-
-
Net income
14.91M
13.29M
8.33M
5.01M
Net profit margin
7.90%
6.71%
4.29%
2.45%
Earnings per share
0.46
0.49
0.48
0.54
Interest and investment income
6.92M
6.75M
6.34M
6.43M
Interest expense
-5.83M
-5.91M
-6.00M
-6.08M
Net interest expenses
1.09M
842.00K
345.00K
347.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
32.69M
36.30M
37.05M
38.06M
Gain or loss from assets sale
-3.38M
-
13.76M
-103.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps